Have a feature idea you'd love to see implemented?
Let us know!
STRO Sutro Biopharma Inc
Price (delayed)
$3.46
Market cap
$283.59M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.83
Enterprise value
$218.48M
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.
Highlights
Sutro Biopharma's revenue has surged by 198% YoY and by 10% QoQ
The gross profit has soared by 198% YoY and by 10% from the previous quarter
STRO's net income is up by 13% YoY but it is down by 8% from the previous quarter
The quick ratio has contracted by 44% YoY and by 23% from the previous quarter
Key stats
What are the main financial stats of STRO
Market
Valuations
Earnings
Shares outstanding
81.96M
Market cap
$283.59M
Enterprise value
$218.48M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.86
Price to sales (P/S)
1.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.29
Revenue
$169.36M
EBIT
-$97.55M
EBITDA
-$85.72M
Free cash flow
-$77.69M
Per share
Balance sheet
Liquidity
EPS
-$1.83
Free cash flow per share
-$0.96
Book value per share
$1.86
Revenue per share
$2.09
TBVPS
$6.02
Total assets
$489.04M
Total liabilities
$336.87M
Debt
$26.53M
Equity
$152.18M
Working capital
$313.49M
Debt to equity
0.17
Current ratio
3.41
Quick ratio
3.34
Net debt/EBITDA
0.76
Margins
Efficiency
Dividend
EBITDA margin
-50.6%
Gross margin
100%
Net margin
-73.5%
Operating margin
-62.7%
Return on assets
-27.7%
Return on equity
-97.2%
Return on invested capital
-31.6%
Return on capital employed
-27.2%
Return on sales
-57.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
STRO stock price
How has the Sutro Biopharma stock price performed over time
Intraday
-1.7%
1 week
-1.42%
1 month
-19.91%
1 year
-9.66%
YTD
-19.35%
QTD
0%
Financial performance
How have Sutro Biopharma's revenue and profit performed over time
Revenue
$169.36M
Gross profit
$169.36M
Operating income
-$106.14M
Net income
-$124.45M
Gross margin
100%
Net margin
-73.5%
Sutro Biopharma's revenue has surged by 198% YoY and by 10% QoQ
The gross profit has soared by 198% YoY and by 10% from the previous quarter
STRO's operating margin has soared by 78% YoY and by 7% QoQ
The company's net margin has surged by 71% YoY
Growth
What is Sutro Biopharma's growth rate over time
Valuation
What is Sutro Biopharma stock price valuation
P/E
N/A
P/B
1.86
P/S
1.66
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.29
STRO's EPS is up by 26% YoY and by 2.7% from the previous quarter
The equity has surged by 55% since the previous quarter
The stock's price to book (P/B) is 14% less than its last 4 quarters average of 2.2 and 10% less than its 5-year quarterly average of 2.1
Sutro Biopharma's revenue has surged by 198% YoY and by 10% QoQ
The stock's price to sales (P/S) is 77% less than its 5-year quarterly average of 7.4 and 30% less than its last 4 quarters average of 2.4
Efficiency
How efficient is Sutro Biopharma business performance
STRO's ROS has soared by 76% YoY but it is down by 2.3% from the previous quarter
Sutro Biopharma's ROE has decreased by 34% YoY and by 9% from the previous quarter
STRO's return on invested capital is up by 34% year-on-year but it is down by 4.3% since the previous quarter
STRO's return on assets is up by 21% year-on-year but it is down by 7% since the previous quarter
Dividends
What is STRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for STRO.
Financial health
How did Sutro Biopharma financials performed over time
STRO's total assets is 45% greater than its total liabilities
Sutro Biopharma's current ratio has decreased by 44% YoY and by 24% from the previous quarter
The quick ratio has contracted by 44% YoY and by 23% from the previous quarter
The company's debt is 83% lower than its equity
The equity has surged by 55% since the previous quarter
Sutro Biopharma's debt to equity has decreased by 41% from the previous quarter and by 39% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.